Navigation Links
Preventing or reducing enlarged heart decreases risk of heart failure
Date:9/13/2007

NEW YORK (Sept. 10, 2007) -- For high-blood-pressure patients, preventing or reducing enlarged heart (left ventricular hypertrophy or LVH) reduces risk of heart failure. The study is published in the Sept. 4 Annals of Internal Medicine and led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

An estimated 20 percent of all high-blood-pressure patients, or 12 million Americans, have LVH and are at increased risk of developing heart failure.

While the direct relationship between levels of LVH in patients with high blood pressure and risk of cardiac complications -- including death, heart attack, stroke and atrial fibrillation -- has previously been demonstrated by NewYork-Presbyterian/Weill Cornell researchers (JAMA, 2004 and 2006), the new study is the first to demonstrate that prevention or regression of LVH reduces risk of being hospitalized for heart failure -- and that this relationship exists independent of therapy type and the benefits of blood pressure reduction. The study uses data from the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study conducted between 1995 and 2001.

"The message for high-blood-pressure patients is that by preventing or reversing enlarged heart, there is an added benefit, over and above any reduction in blood pressure, of lowering risk for heart failure," says the study's principal investigator, Dr. Peter Okin, director of clinical affairs and professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medical College and a cardiologist at NewYork-Presbyterian/Weill Cornell.

"And, from a public health perspective, our findings suggest that blood-pressure therapy targeted at regression or prevention of LVH may help to blunt the increasing incidence of heart failure," continues Dr. Okin.

Of the 8,479 high-blood-pressure patients without heart failure followed in the new study, 214 were hospitalized for heart failure (2.5 percent). Among these patients, a greater than average reduction of LVH was associated with a 43-percent reduced risk of heart failure, and remained associated with a 36-percent reduced risk after adjusting for other risk factors. Levels of LVH were determined by electrocardiograph (ECG) using Cornell voltage-duration product criteria. (Cornell voltage-duration product, an ECG pattern associated with presence of LVH, was developed at Weill Cornell Medical College in 1992 and is currently in use worldwide.)

Previous studies have shown that hypertension doubles the lifetime risk for developing heart failure in men and triples the risk in women, accounting for 39 percent of new heart failure cases in men and 59 percent of incident cases in women.

All patients in the LIFE study received Losartan- or atenolol-based therapies. In a previous LIFE study paper (Circulation, 2003), Weill Cornell researchers found the angiotensin receptor antagonist drug Losartan had a decided advantage over another anti-hypertensive drug, the beta-blocker atenolol, in reducing LVH.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Preventing mental decline in the aged
2. Preventing white coat hypertension
3. Green tea beneficial in preventing osteoarthritis
4. Preventing Childhood Deaths
5. Preventing Vision Loss
6. Preventing Vision Loss
7. Preventing Colorectal Cancer
8. Preventing Prostate Cancer
9. Lycopene Can Help In Preventing Prostate Cancer
10. Heart Drug Also Effective In Preventing Specific Causes Of Death
11. Preventing cavities in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... ... 2017 , ... The Military Officers Association of America (MOAA) announced its support ... retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff director ... with the issues and challenges veterans face with the VA. Following a 30-year career ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South ... selected 21 leaders from government, business and civil society in 11 countries across the ... this fall, engaging in a transformative exchange of knowledge and ideas with the leading ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
Breaking Medicine Technology: